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Mitochondrial respiratory 
dysfunction due to the conversion 
of substituted cathinones to 
methylbenzamides in SH-SY5Y 
cells
Bjørnar den Hollander1, Mira Sundström2, Anna Pelander2, Antti Siltanen1, Ilkka Ojanperä2, 
Eero Mervaala1, Esa R. Korpi1 & Esko Kankuri1
The increased use of cathinone-type designer drugs, known as legal highs, has led to concerns 
about their potential neurotoxicity due to their similarity to methamphetamine (METH). Therefore, 
closer investigations of their toxic effects are needed. We investigated the effects of the cathinones 
4-methylmethcathinone (4-MMC) and 3,4-methylenedioxymethcathinone (MDMC) and the 
amphetamine METH on cytotoxicity and mitochondrial respiration in SH-SY5Y neuroblastoma 
cells. We also investigated the contribution of reactive species, dopamine, Bcl-2 and tumor 
necrosis factor α (TNFα) on toxicity. Finally, we investigated the effect of cathinone breakdown 
products using ultra-high performance liquid chromatography/high-resolution time-of-flight mass 
spectrometry and studied their involvement in toxicity. We observed dose-dependent increases in 
cytotoxicity and decreases in mitochondrial respiration following treatment with all cathinones and 
amphetamines. Glutathione depletion increases amphetamine, but not cathinone toxicity. Bcl-2 and 
TNFα pathways are involved in toxicity but dopamine levels are not. We also show that cathinones, 
but not amphetamines, spontaneously produce reactive species and cytotoxic methylbenzamide 
breakdown products when in aqueous solution. These results provide an important first insight into 
the mechanisms of cathinone cytotoxicity and pave the way for further studies on cathinone toxicity 
in vivo.
The term “legal highs” is commonly used to refer to a range of novel psychoactive substances that 
are sold for recreational use. However, little is known yet about their potential neurotoxicities and 
long-term effects. A class of substances known as substituted cathinones is of particular interest. 
Substituted cathinones include substances such as 4-methylmethcathinone (4-MMC, “mephedrone”) 
and 3,4-methylenedioxymethcathinone (MDMC, “methylone”)1,2. These cathinones are closely related, 
in their chemical structure and in their pharmacological actions, to those of the amphetamines metham-
phetamine (METH) and 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”)3,4. It is known that 
amphetamines can produce neurotoxicity by several mechanisms, such as increasing levels of oxidative 
stress and inhibiting mitochondrial function5. This raises an essential question as to whether the substi-
tuted cathinones work by similar mechanisms to produce effects involved in neurotoxicity.
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Recent studies show that cathinones are less likely than amphetamines to produce persistent decreases 
in markers of neurotoxicity3,6. Such markers include brain dopamine (DA), DA transporters (DAT) or 
the DA biosynthesis enzyme tyrosine hydroxylase (TH) in rodents3,6. On the other hand, cathinones 
appear to potentiate the toxicity of amphetamines when the two are co-administered. Additionally, they 
may be toxic when administered at high ambient temperatures, and effects of cathinones on memory 
function have also been observed7–9. Furthermore, recent studies show that cathinones can produce 
similar toxicity as amphetamines in vitro. For instance, Araujo et al.10 reported cytotoxicity in response 
to both amphetamines and cathinones in primary cultured rat hepatocytes. Moreover, we showed previ-
ously that cytotoxicity and decreases in mitochondrial respiration occur in response to both cathinones 
and amphetamines in cultured neuronal cells11. Cytotoxicity following both cathinones and ampheta-
mines administration was also observed in Chinese hamster ovary cells that had been transfected with 
monoamine transporters12.
In order to understand better the potential risks for human cathinone users and the discrepancies 
between in vivo and in vitro derived data, more detailed investigations into the mechanisms involved in 
cytotoxic effects of cathinones are required. A few years ago, the interesting observation was made that 
the cathinone 4-MMC molecule rapidly breaks down into N-4-dimethylbenzamide (DMBA) under alka-
line conditions13. Subsequently, we demonstrated that MDMC also breaks down into its corresponding 
3,4-methylenedioxy-N-methylbenzamide (MDMBA) and that this breakdown can also effectively occur 
at physiological pH (pH 7.35) in the presence of an electron acceptor11. However, the contribution of 
these methylbenzamides to neuronal cell toxicity remains to be determined.
Here, we explore and compare mechanisms involved in the cytotoxic response to cathinones and 
their methylbenzamide breakdown products with those of typical amphetamines. For this purpose, we 
used the SH-SY5Y neuroblastoma cell line as this cell line shows many neuronal characteristics and is 
a well-established model in research on amphetamine neurotoxicity14,15. Our broad objective was to 
study toxicity for DA producing and non-DA producing cells, thus we describe experiments using an 
undifferentiated cell line and also cells that had been subjected to a differentiation protocol known to 
induce a specific DA neuron-like phenotype16. Our principal focus was on the effects of cathinones and 
amphetamines on cytotoxicity and mitochondrial function in addition to studying the mechanisms that 
include reactive oxygen species (ROS) and tumor necrosis factor α (TNF α ). Importantly, we demon-
strate that the methylbenzamide breakdown products that are produced from cathinones in aqueous 
solutions under normal physiological conditions may contribute to the observed effects of cytotoxicity 
and mitochondrial dysfunction.
Methods
Drugs and reagents. Racemic 4-MMC and MDMC were acquired from the Department of Forensic 
Medicine, Hjelt Institute, University of Helsinki. The compounds were analyzed for purity by gas chro-
matography and Fourier transform infrared spectroscopy and found to be pure (> 95%) hydrochloride 
salts. MDMA (catalog ID THC-1347) was acquired from THC Pharm GmbH (Frankfurt, Germany); 
DMBA (catalog ID H56446) from Alfa Aesar GmbH (Karlsruhe, Germany) and MDMBA (catalog ID 
10W-0825 from Key Organics (Camelford, UK). METH (catalog ID M8750) and other reagents, unless 
otherwise specified, were acquired from Sigma-Aldrich (St. Louis, MO, USA) and were all of analytical 
quality. All drugs used in the experiments were dissolved in their respective vehicle (growth medium, 
water or phosphate-buffered saline) solutions. The DMBA and MDMBA drugs are not water-soluble thus 
they were dissolved in a vehicle containing 1% dimethyl sulfoxide.
SH-SY5Y cell culture. SH-SY5Y neuroblastoma cells were obtained from ATCC (Middlesex, UK). 
They were maintained between passages 6 and 20 in Dulbecco’s Modified Eagle Medium (DMEM/F12), 
which contains 10% fetal bovine serum, penicillin (100 U/ml), streptomycin (100 μ g/ml) and ampho-
tericin B (0.25 μ g/ml) (all obtained from Gibco - Invitrogen, Paisley, UK) and kept in an incubator at a 
temperature of 37 °C with 5% CO2. Experiments were done on undifferentiated cells and also on cells 
differentiated by a 3-day treatment with 10 μ M retinoic acid followed by a 3-day treatment with 80 nM 
12-O-tetradecanoylphorbol-13-acetate (RA-TPA-differentiated cells), which is known to induce a more 
dopamine neuron-like phenotype16.
Cytotoxicity assays. SH-SY5Y cells were plated on 96-well plates at a density of ± 5000 cells/100 μ L 
well and grown for 4 or 6 days (RA-TPA-differentiated cells) before the medium was replaced with medium 
containing one of the following: METH, MDMA, 4-MMC or MDMC (2.5–2000 μ M). Cytotoxicity of each 
drug molecule was determined by assessing the amount of lactate dehydrogenase (LDH) released into the 
growth medium, which was then assayed by the Cytotoxicity Detection Kit (Roche, Basel, Switzerland) 
according to the manufacturer’s instructions. The LDH concentrations in the dose-response experiments 
and buthionine sulfoximine (BSO) experiments were measured in the cells and also the medium at 24 h 
and 48 h after the drug treatment. The LDH release was calculated by dividing the LDH content in the 
medium by the total amount of LDH in medium and the cells at both time points. The mean values of 
the two measurements are shown. Other determinations of LDH for each drug treatment were made 
at 48 h only. In experiments where drug treatments were combined with the DAT blocker GBR12909 
(1 μ M), the cells were pre-treated for 1 h with GBR12909 prior to application of the drug in combination 
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with GBR12909. In experiments where drug treatments were combined with BSO, the cells were treated 
with BSO for 24 h prior to application of the drug in combination with BSO.
Bcl-2 overexpression. SH-SY5Y cells were plated at 10,000/cm2 for transfection. The cells were trans-
fected 24 h later with the retroviral vector that carries the human BCL-2 gene (pBABEpuro, Biomedicum 
Functional Genomics Unit, University of Helsinki). Transfection was carried out with 8 μ g/ml polybrene 
at 1200 g centrifugation for 1 h. Incubation was continued at 37 °C for 6 h, after which 2 volumes of 
culture medium was added to reduce the polybrene toxicity The procedure was repeated 24 h later to 
increase transfection efficiency. The cells were incubated with 1 μ g/ml puromycin for 48 h to increase the 
ratio of BCL-2-transfected cells. Puromycin selection was repeated during the next passage. The antia-
poptotic function of this construct has been previously validated and the overexpression of the Bcl-2 does 
not influence the expression of other genes17.
Analysis of gene expression. Total RNA was isolated from undifferentiated and RA-TPA differenti-
ated SH-SY5Y cells by using the RNEasy Mini Kit (Qiagen, Hilden, Germany). Sample RNA integrity and 
quality were confirmed by the Agilent Bioanalyzer 2100 (Agilent Technologies, Santa Clara, CA, USA). 
100 ng of total RNA was primed using oligo-dT(T7) primers and converted to cDNA with SuperScript 
III Reverse Transcriptase. cDNA was then converted to double-stranded cDNA using DNA Polymerase 
(Life Technologies, Carlsbad, CA, USA). The double-stranded cDNA template was amplified and labe-
led by in vitro transcription to generate multiple copies of biotinylated cRNA. Biotinylated cRNA was 
purified by RNeasy Mini Kit and was hybridized to HumanHT-12 v4 Expression BeadChips (Illumina 
Inc. San Diego, CA, USA) for 18 hours at 58 °C. BeadChips were washed, blocked and stained with 
streptavidin-Cy3 and scanned by using the Illumina iScan (Illumina Inc.), according to the manufactur-
er’s protocol. The raw data were extracted using Illumina GenomeStudio software. The gene expression 
fold-changes were calculated from the background-corrected and the quantile-normalized data.
TNFα measurement. The TNFα levels of the cells were measured by using the AlphaLISA Human 
TNFα Research Immunoassay Kit by PerkinElmer (Waltham, MA). Cells were grown normally and 
treated with various drugs for 48 h as described above. Subsequently, TNFα content in the medium was 
measured according to the manufacturer’s instructions. Briefly, 5 μ L of medium was placed in wells of 
a 96-well AlphaLISA assay plate and subsequently, acceptor beads (final concentration: 10 μ g/ml) were 
added to the wells and the plate was incubated for 30 min at 23 °C. Next, anti-analyte antibody (final 
concentration: 1 nM) was added and the plate incubated for 60 min. Finally, donor beads (final concen-
tration: 40 μ g/ml) were added to the wells and the plate incubated for another 30 min before the final 
readout was made on an Envision Multilabel Reader (PerkinElmer). Concentrations of TNFα in the 
medium were calculated when their plots were read against those of standard curves produced by using 
the manufacturer-provided TNFα .
Western Blotting. Western blotting was carried out as detailed previously18,19. Briefly, cells were cul-
tured on 96-well plates as detailed above. Cells with or without retinoic acid differentiation received 
either 2 mM mephedrone or vehicle. After 48 hours, cells in each well were harvested into 75 μ l cell 
lysis buffer (1% Triton-X100, 20 mM Tris Base, 100 mM NaCl, 1 mM EDTA, pH adjusted to 7.4; one 
tablet of complete Mini EDTA-free Protease inhibitors (Roche Diagnostics GmbH, Mannheim, Germany 
was added to 10 ml of buffer). Cells from 8 wells were pooled as one sample. The samples were soni-
cated for 3 × 10 s, and protein content was analyzed using the Pierce™ BCA Protein Assay Kit (Thermo 
Scientific, Rockford, IL). Protein content in samples from each experiment was equalized by diluting the 
samples with high protein content to the protein concentration of the most dilute sample in appropri-
ate amounts of lysis buffer and 5x concentrated sample buffer (Lane Marker Reducing Sample Buffer, 
cat#3900, Thermo Scientific). Samples were heated in a block-heater at 97 °C for 5 min, and were stored 
at − 20 °C. For western blotting samples were thawed and re-heated at 97 °C for 2 min. Controls and 
samples from a single experiment were run on the same gel to enable comparative analysis. An equal 
sample volume of 20 μ l was added to each well of Mini-Protean® TGX™ 4–20% Precast Gels (Bio-Rad, 
Hercules, CA). Electrophoresis was carried out in Tris/Glycine/SDS buffer (Bio-Rad #161-0732) followed 
by blotting to nitrocellulose membranes in transfer buffer (containing 25 mM Tris, 192 mM glycine, 20% 
methanol, pH 8.3) as detailed previously18,19 After blotting membranes were incubated for 1 h in 2.5% 
skimmed milk powder Tris buffer pH7.5 followed by a 2 h-incubation with the primary antibody (p53: 
mouse anti-p53: clone DO-1, sc-126 and rabbit anti-p53, sc-6243 were used for verification of results in 
consecutive runs; both from Santa Cruz Biotech, Dallas, TX). Membranes were then incubated for 1 h 
with secondary antibodies (goat-anti-rabbit IRDye® 800CW and goat-anti-mouse IRDye® 680LT; both 
from Li-Cor Biosciences, Lincoln, NE). Signal detection was carried out using Li-Cor Odyssey system 
and ImageStudio 2.0.38 software (both from Li-Cor Biosciences, Lincoln, NE). Quantification of band 
intensity in relative fluorescence units was carried out using the gel analysis feature of Fiji software20. 
Fold-changes between band intensities of controls and samples on same membranes were compared 
assigning the control band intensity to 1.
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Fluorometric detection of H2O2 in Oxygraph-2k. The H2O2 production levels that resulted from 
METH, MDMA, 4-MMC or MDMC in aqueous solution were determined by real-time fluoromet-
ric detection of H2O2 using an Amplex Red/horseradish peroxidase (HRP) assay in an Oxygraph-2k 
respirometer instrument that was fitted with a fluorescence module (Oroboros Instruments GmbH, 
Innsbruck, Austria). Prior to the start of the assay, Amplex Red and HRP (final concentrations of 5 μ M 
and 10 U/ml, respectively) were added to the chambers of the Oxygraph-2k instrument. After obtaining 
a steady 5 min baseline, known quantities of one of the following: METH, MDMA, 4-MMC, MDMC 
(final concentrations of 20 mM) or water were added to the Oxygraph-2k chambers and the changes in 
fluorescence over the next 5 min were measured. Drug-induced increases in cumulative H2O2 production 
were determined by dividing the slope measured after drug injections by the slope obtained prior to the 
injection of drugs into the chambers.
Assessment of mitochondrial function. The effects of the drugs on the mitochondrial oxygen con-
sumption rate (OCR) in the SH-SY5Y cells were assessed using a Seahorse Bioscience XFe96 analyzer 
(Massachusetts, USA) in combination with the Seahorse Bioscience XF Cell Mito Stress Test assay kit. 
In this assay, subsequent additions of the ATP synthase inhibitor oligomycin, the mitochondrial uncou-
pler carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone (FCCP) and the complex I + II inhibitors 
rotenone + antimycin A into the assay medium provided insight into different aspects of mitochondrial 
function. Experiments were performed on intact, adherent cells and also on permeabilized cells.
Intact cells. Cells were plated at a density of ± 10,000 cells/80 μ L well in 96-well assay plates (Seahorse 
Bioscience) into standard growth medium for SH-SY5Y cells and grown for 4 days or allowed to dif-
ferentiate into RA-TPA-differentiated cells for 6 days before the medium was replaced by a medium 
containing one of the following: METH, MDMA, 4-MMC or MDMC (0.5–2 mM). After 24 h, the nor-
mal medium was replaced by assay medium consisting of XF Base Medium (Seahorse Bioscience) with 
added 10 mM glucose, 10 mM pyruvic acid, and 1 mM L-glutamine. Subsequently, the analysis of OCR 
was performed in a Seahorse XFe96 analyzer according to the manufacturer’s instructions. The OCR 
values were obtained during baseline (prior to addition of any Mito Stress Test substances) and after the 
addition of 1 μ M oligomycin, 0.5 mM FCCP and 1 μ M rotenone + 1 μ M antimycin A. Prior to analysis, 
data were corrected by withdrawing non-mitochondrial respiration (measured after the injection of rote-
none + antimycin A) from all measured OCR values.
Permeabilized cells. Undifferentiated cells were plated at a density of ± 40,000 cells/80 μ L well in 96-well 
assay plates (Seahorse Bioscience) into a normal growth medium and grown for 24 h before the growth 
medium was replaced by a mannitol-sucrose buffer that consisted of 220 mM mannitol, 70 mM sucrose, 
10 mM KH2PO4, 5 mM MgCl2, 2 mM HEPES and 1 mM EGTA in addition to 10 mM glutamate, 2 mM 
malate, 5 mM pyruvate, 1 mM ATP, 4 mM ADP. Furthermore, 4 mg/ml bovine serum albumin and 2 nM 
recombinant perfringolysin O (XF Plasma Membrane Permeabilizer, Seahorse Bioscience) were added to 
the buffer directly prior the start of the experiments. After obtaining baseline measurements were taken 
the drugs (METH, 4-MMC, DMBA, MDMC and MDMBA, all 2 mM) were added to the wells according 
to the study allocation and allowed to incubate for 10 min prior to the addition of 5 μ M oligomycin, 5 μ M 
FCCP and 2 μ M rotenone + 2 μ M antimycin A.
Analysis of DA and cathinone breakdown products. Dopamine. DA levels were assessed using 
high-performance liquid chromatography with electrochemical detection (HPLC-ED) under conditions 
similar to those described previously8. Cells were plated into 6-well plates and grown or differenti-
ated normally. Additionally, RA-TPA-differentiated cells were also grown in the medium with 0.5 mM 
α -methyl-para-tyrosine added during the last 3 days of differentiated together with the TPA. Following 
the growth and differentiation protocols, cells from 3 wells were pooled into one sample which was pre-
pared by brief sonication in 2% perchloric acid and centrifugation (at 15,000 g for 30 min). Subsequently, 
10 μ L of supernatant was injected into the HPLC system and analyzed for the DA content. The mobile 
phase consisted of purified water with 8% methanol, 50 mM citric acid, 1.5 mM 1-octanesulfonic acid, 
0.05 mM EDTA and 50 mM phosphoric acid. The retention time for DA was 7.45 min, and DA concen-
trations were calculated by being read against linear standard curves.
Cathinone breakdown product. The formation of the MDMC breakdown product MDMBA was assessed 
by dissolving the compounds in a pH 12 buffer and measuring the level of breakdown product following 
0, 24, and 48 h incubation at 37 °C. The amount of 4-MMC breakdown product DMBA in cellular growth 
medium following a 48 h treatment of SH-SY5Y cells with 4-MMC both with and without GBR12909 was 
also measured. An ultra-high performance liquid chromatography/high-resolution time-of-flight mass 
spectrometry (UHPLC-HR-TOFMS) method was used for the analysis of the samples. The chromato-
graphic and mass spectrometric conditions were similar to those described previously21. The monitored 
compound signals were extracted at m/z-window of 5 mDa. The median mass accuracy and isotopic 
pattern match of the measured compounds were 0.3 mDa and 4, respectively.
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Statistics. Data obtained from the cytotoxicity and mitochondrial respiration experiments were 
analyzed using one-way ANOVAs with Fisher’s Least Significant Difference post hoc tests. Data of the 
cytotoxicity experiments based on the LDH release observed in control wells (untreated cells) were nor-
malized. Pairwise comparisons were made using the independent samples by the paired t test to analyze 
data from the 4-MMC ± GBR12909 LDH release experiments and also to analyze those data from the 
TNFα and HPLC DA experiments. Statistical significance was set at values p < 0.05. All data are pre-
sented as mean ± SEM, unless otherwise specified.
Results
Validation of dopamine neuron-like phenotype. The DA-ergic phenotype were validated if the 
levels of cellular DA were measured in both undifferentiated and RA-TPA differentiated cells. DA was 
detected in RA-TPA differentiated cells, but not in the undifferentiated cells. Further, a 3-day treatment 
with the TH inhibitor α -methyl-para-tyrosine (0.5 mM) reduced DA-levels to below quantifiable limits 
(Supplementary Fig. 1). This increase in DA levels was associated with a significant increase in the 
expression of TH, and certain other DA-related genes (Supplementary Table 1).
Cytotoxicity and mitochondrial respiration following cathinone- and amphetamine-treat 
ments. Cytotoxicity. The effects of a 48 h treatment with varying doses (2.5–2000 μ M) of METH, 
4-MMC, MDMA or MDMC on the amounts LDH released into the growth media for both undifferen-
tiated and RA-TPA differentiated cells is shown in Fig. 1. For undifferentiated cells, a one-way ANOVAs 
revealed that METH (F8 55 = 5.89, p < 0.001), 4-MMC (F8 47 = 42.80, p < 0.001), MDMA (F8 55 = 41.90, 
p < 0.001) and MDMC (F8 47 = 36.34, p < 0.001) all significantly affected LDH release. Post hoc testing 
showed that all drugs dose-dependently increased LDH release. For RA-TPA differentiated cells, one-way 
ANOVAs also revealed significant effects on LDH release following a 48 h treatment with varying doses 
(2.5–2000 μ M) of METH (F8 55 = 3.79, p < 0.01), 4-MMC (F8 47 = 14.57, p < 0.001), MDMA (F8 55 = 18.60, 
Figure 1. The amounts of lactate dehydrogenase (LDH) released into the medium from SH-SY5Y cells 
during a 48 h treatment as a percentage of the control values for METH, 4-MMC, MDMA or MDMC 
(2.5–2000 μM) in undifferentiated (black circles) and RA-TPA differentiated (squares). The graphs 
show the percentage change in total LDH released into the medium as a function of increasing drug 
concentrations, compared to untreated cells. Only significant differences larger than 5% compared to control 
are marked *p < 0.05; **p < 0.01; ***p < 0.001. N = 5–8 per group.
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p < 0.001) and MDMC (F8 47 = 3.00, p < 0.05), with post hoc tests showing dose-dependent increases in 
cytotoxicity with higher drug concentrations for all drugs besides METH.
Mitochondrial respiration. The effects of a 24 h treatment with varying doses (0.5–2 mM) of METH, 
4-MMC, MDMA or MDMC on mitochondrial respiration in intact cells were determined. Differences in 
baseline respiration and respiration following injection of oligomycin, FCCP and rotenone + antimycin 
A into the assay medium were assessed using separate one-way ANOVAs with post hoc tests and the 
resulting respiratory graph plots are shown in Fig. 2A (undifferentiated cells) or Supplementary Fig. 2B 
(RA-TPA differentiated cells). These graphs show that various drug treatments caused perturbations in 
mitochondrial respiration, although the effects are more pronounced in the undifferentiated cells.
Mechanisms involved in cytotoxicity. Both amphetamines and cathinones exert a clear 
dose-dependent effect on cytotoxicity and mitochondrial respiration, we therefore investigated the 
involvement of several factors known to play a role in amphetamine toxicity.
Dopamine and DAT. The effect of DAT blockade on LDH release following a 48 h treatment with 
METH, 4-MMC, MDMA and MDMC (all 2 mM) was investigated using the DAT blocker GBR12909 
(Fig. 3A). A one-way ANOVA showed a significant effect of treatment (F9 65 = 39.08, p < 0.001) on LDH 
release. Post hoc testing indicated that 4-MMC, MDMA and MDMC all significantly increased LDH 
release compared to untreated cells. However, only the LDH release induced by 4-MMC was partially 
but significantly inhibited by co-treatment with GBR12909 (t8 = 3.23, p < 0.01). Similarly, a significant 
effect of DAT-blockade was found in RA-TPA differentiated cells (F9 64 = 43.12, p < 0.001) with post hoc 
testing showing significant reduction of 4-MMC toxicity due to DAT-blockade with GBR12909 (Fig. 3B). 
Conversely, co-treatment with the TH inhibitor α -methyl-para-tyrosine did not significantly affect the 
toxicity of 4-MMC or METH in RA-TPA differentiated cells (F5 35 = 21.15, p < 0.001). Post hoc test-
ing showed no difference in cytotoxicity between cells treated with or without α -methyl-para-tyrosine 
(Supplementary Fig. 3).
ROS and oxidative stress. The production of ROS were determined by measuring levels of H2O2 pro-
duced by solutions of one of the following: 20 mM METH, 4-MMC, MDMA and MDMC and is shown 
in Supplementary Fig. 4. A steady increase in fluorescence over time can be observed after the addition 
of the cathinones 4-MMC and MDMC, but not after the addition of amphetamines METH, MDMA or 
the vehicle (H2O) control. In the absence of HRP, none of the drugs produced an increase in fluorescence, 
which indicated that the effect was not due to a direct reaction between the cathinones and Amplex Red. 
We subsequently investigated the involvement of oxidative stress-mediated processes in the cytotoxic 
response of SH-SY5Y cells to amphetamines and cathinones by depleting cellular glutathione with 4 mM 
BSO (Fig. 4.) A significant effect of treatment was found on LDH release (F9 78 = 158.6, p < 0.001). Post 
hoc testing revealed that BSO strongly increased the LDH release due to METH and MDMA, while in 
fact reducing 4-MMC-induced LDH release and having no effect on MDMC-induced LDH release.
Bcl-2 involvement. The involvement of the anti-apoptotic mitochondrial Bcl-2pathway in drug-induced 
cytotoxicity was investigated by comparing the amount of LDH release in normal and Bcl-2 overexpress-
ing SH-SY5Y cells following a 48 h treatment with 2 mM METH, 4-MMC, MDMA or MDMC (Fig. 5). 
The percentage LDH release compared to untreated cells was calculated for both normal and Bcl-2 over-
expressing cells. A one-way ANOVA of the resulting data demonstrated a significant effect (F8 53 = 84.45, 
p < 0,001), and subsequent post hoc tests showed that Bcl-2/BCL-2 overexpression partially but signifi-
cantly attenuated both 4-MMC and MDMA cytotoxicity, but did not affect MDMC-induced cytotoxicity.
TNFα. The effects of individual treatments 2 mM 4-MMC, METH, MDMC or MDMA alone or in 
combination with GBR12909 on medium TNFα levels are shown in Fig.  6. Treatment significantly 
affected TNFα levels (F9 45 = 2.66, p < 0.05), and post hoc testing revealed that only 4-MMC treatment 
significantly increased medium TNFα levels. Co-treatment with GBR12909 tended to attenuate the 
4-MMC-induced increase in TNFα levels (p = 0.064).
p53. The effects of a 48 h treatment with 4-MMC on p53 protein levels is shown in Fig. 7. A significant 
induction of p53 was observed in cells treated with 4-MMC and RA, compared to cells treated only with 
RA (t4 = 6.47, p < 0.01). A large variance was observed in p53 levels of control cells treated with 4-MMC 
and the observed increase in p53 levels was therefore not significant (t4 = 1.62, ns).
Detection of methylbenzamide breakdown products. We measured DMBA and MDMBA lev-
els 0 and 48 h after dissolving 2 mM 4-MMC or MDMC in pH 12 phosphate-buffered saline in order 
to demonstrate the spontaneous breakdown of cathinones over time. The quantity of DMBA was also 
measured in the SH-SY5Y medium following 4-MMC treatment to demonstrate that breakdown also 
occurs under physiological conditions.
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Figure 2. Oxygen consumption rate (OCR) of undifferentiated cells (A) or RA-TPA differentiated 
cells (B) that had been previously exposed to one of the following METH, 4-MMC, MDMA or MDMC 
(0.5–2.0 mM) for 24h. The graphs show the baseline OCR (prior to any injections) the OCR after injection 
of the complex IV inhibitor oligomycin (Oli), the uncoupler carbonyl cyanide 4-(trifluoromethoxy)
phenylhydrazone (FCCP) and a combined injection of rotenone + antimycin A (Rot + Ama) (final 
concentration of all compounds was 1 μ M). Measurements were performed using the Seahorse XFe96 
instrument. *p < 0.05; **p < 0.01; ***p < 0.001 compared to control (shown as a dashed line). N = 5–8 per 
group.
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Figure 3. The effect of GBR12909 on LDH release from SH-SY5Y cells in response to 4-MMC, METH, 
MDMC or MDMA (all 2 mM) in (A) undifferentiated cells and (B) RA-TPA differentiated cells. Cells 
were treated with GBR12909 or the vehicle for 1 h prior to exposure to 4-MMC, METH, MDMC or MDMA. 
**p < 0.01; ***p < 0.001. N = 6–10 per group.
Figure 4. The effect of buthionine sulfiximine (BSO 4 mM) on LDH release by 4-MMC, MDMC, MDMA 
or METH (all 2 mM). Cells were treated with BSO for 24 h prior to drug exposure as well as during drug 
the 48 h drug exposure. **p < 0.01; ***p < 0.001. N = 7–8 per group.
Figure 5. Effect of Bcl-2 overexpression on cytotoxicity (LDH release into medium) induced by a 48h 
treatment of SH-SY5Y with 4-MMC, METH, MDMC or MDMA (all 2 mM). Data are expressed as a 
percentage LDH release compared to respective (normal or Bcl-2 overexpressing) untreated control cells. 
**p < 0.01; ***p < 0.001. N = 6 per group.
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pH 12 phosphate buffer. We performed UHPLC-HR-TOFMS on highly alkaline samples of 4-MMC 
and MDMC in order to compare the findings with those of Tsujikawa et al.13. The UHPLC-HR-TOFMS 
data indicated an accumulation of both DMBA and MDMBA breakdown products at 48 hours, which 
is in accordance with the findings reported by Tsujikawa et al.13 under alkaline pH conditions. The ion 
chromatograms are shown in Supplementary Fig. 5.
SH-SY5Y growth medium. The amount of DMBA breakdown product in SH-SY5Y growth medium 
following a 48 h treatment of SH-SY5Y cells with 4-MMC in the presence or absence of GBR12909 is pre-
sented in Fig. 8A and shows a clear increase in medium DMBA levels when GBR12909 is present. These 
data suggest that DMBA may also be produced under physiological conditions and that DAT inhibition 
(as evidenced here by the effect of GBR12909) may prevent its cellular uptake.
Cytotoxicity and mitochondrial respiration following methylbenzamide-treatment. Cytotox
icity. The amount of LDH released into the medium following a 48 h treatment with 2 mM DMBA or 
MDMBA, alone or in combination with GBR12909 was measured and is shown in Fig. 8B. A one-way 
ANOVA revealed a significant effect of treatment on LDH release (F5 25 = 11.52, p < 0.001). Post hoc tests 
revealed that both DMBA and MDMBA caused a significant increase in LDH release compared to the 
untreated cells and that this increase was fully blocked by co-treatment with DAT blocker GBR12909.
Mitochondrial respiration. The effects of 4-MMC and DMBA; MDMC and MDMBA in addition to 
METH on mitochondrial respiration were subsequently assessed in permeabilized SH-SY5Y cells. The 
respiratory rate plots (Fig. 9) show differences in baseline OCR before and during the 10 min incubation 
with the drugs. OCR following injection of oligomycin, FCCP and rotenone + antimycin A into the assay 
medium are also shown in Fig.  8. These data show that DMBA and MDMBA cause a rapid reduction 
in both baseline and maximum respiration. METH does not affect baseline respiration, but eventually 
produces a reduction in the maximum respiration at two time points. Conversely, the cathinones 4-MMC 
and MDMC have little effect on respiration, except from a slight reduction in maximum respiration after 
MDMC, but only at one time point.
Figure 6. The effect of a 48 h treatment with 2 mM 4-MMC, METH, MDMC or MDMA alone or in 
combination with 1 μM GBR12909 on levels of tumor necrosis factor α (TNF α) in cellular growth 
medium. *p < 0.05, Co-treatment with GBR12909 tended to attenuate the 4-MMC-induced increase in 
TNFα levels #p = 0.064. N = 4–10 per group.
Figure 7. Expression of p53 in control and RA-treated SH-SY5Y cells with or without 4-MMC (2 mM) 
after 48 hours. Relative fluorescence intensity values were obtained from western blots of samples from 
three independent experiments. Data is presented as the mean fold change + SEM (N = 3) when comparing 
4-MMC-treated samples with representative controls receiving vehicle only (control) or RA + vehicle (RA). 
**p < 0.01.
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Discussion
We showed that both amphetamines and cathinones can produce a dose-dependent cytotoxic effect 
and decrease mitochondrial respiration. The cytotoxic effect of cathinone 4-MMC is larger than that of 
METH, and can be partially prevented by DAT blockade and overexpression of mitochondria-protective 
anti-apoptotic Bcl-2. Meanwhile, 4-MMC also caused induction of p53. However, depletion of DA per 
se did not significantly affect toxicity. We found that cathinones, spontaneously produce ROS in aque-
ous solution as measured by the Amplex Red/ROS accumulation assay, whereas amphetamines do not. 
Furthermore, depletion of cellular glutathione strongly increases amphetamine toxicity, but has no effect 
or actually decreases, cathinone toxicity. We also found that the conversion of 4-MMC to its corre-
sponding methylbenzamide breakdown product can occur under physiological conditions, and that 
treatment with methylbenzamides alone is sufficient to produce cytotoxicity and decrease mitochondrial 
respiration.
The breakdown of cathinones into their corresponding methylbenzamides has been described previ-
ously to occur under conditions of high pH, or in the presence of electron acceptors11,13. Here, we showed 
that the breakdown can also occur under normal physiological conditions in cellular growth media with 
cells present. This observation is of particular interest because methylbenzamides themselves appear to 
cause cytotoxicity and affect mitochondrial respiration. Detailed quantitative measurements of DMBA 
and MDMBA and their formation under physiological conditions both in vitro and in vivo are therefore 
warranted. The cytotoxicity observed after cathinone treatment can be separated into multiple compo-
nents: one that is directly due to the effect of the cathinones themselves and a second component that is 
due to their methylbenzamide breakdown products (represented schematically in Fig. 10). Furthermore, 
interactions between the two may also occur. Although it is difficult to quantify the exact contribution 
of each metabolite makes to the total toxicity using the experimental design described here, our present 
study’s findings do support the conclusion that cathinones themselves may be less toxic than suggested 
by continuous-treatment exposure in vitro. This conclusion is supported by in vivo data on neurotoxic-
ity3,22. An important two-part question therefore is to what extent does the observed in vitro breakdown 
of cathinones into their respective methylbenzamides products proceed, and can the toxicity of these 
methylbenzamides products be reproduced in in vivo studies? The breakdown appears to be a relatively 
slow continuous process as opposed to a rapid reaction, thus it is likely that the effects of the breakdown 
products in vivo may be limited to periods of very long exposure to cathinones, such as multi-day 
binge use, and not be evident after only one or a few doses/treatments with the drug. Furthermore, the 
occurrence of these breakdown products may be helpful in explaining why cathinone toxicity can be 
precipitated by certain factors, including hyperthermia, as these factors may influence the rate at which 
cathinones are converted to methylbenzamides9,23.
The observed increase in TH, mrNA and DA levels confirm the successful induction of a DA neuron-like 
phenotype using the RA-TPA differentiation protocol described by Presgraves and colleagues16. It was 
previously shown that the differentiation by RA-TPA treatment also produces a more resistant cellular 
phenotype, which has been linked to the upregulation of Nrf2 and NAD(P)H quinone oxidoreductase 1, 
Figure 8. (A) Extracted ion chromatograms of DMBA in SH-SY5Y cell growth medium following 
an incubation of 48 h for SH-SY5Y cells with 4-MMC in the presence (blue) or absence(red) of 1 μ M 
GBR12909. (B) The effect of a 48 h treatment with DMBA or MDMBA either alone, or in combination with 
the DAT blocker GBR12909, which fully blocked the cytotoxicity produced by both drugs. GBR12909 was 
applied 30 m before addition of DMBA or MDMBA. **p < 0.01; ***p < 0.001. N = 3–10 per group.
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both of which play an important role in the endogenous antioxidant response and redox balance24. Our 
results are largely consistent with this as both the cytotoxic response and the decrease in mitochondrial 
respiration we observed after drug treatments was generally lower in RA-TPA differentiated cells, com-
pared to undifferentiated cells. The effects of METH, 4-MMC and MDMC on cytotoxicity and of 4-MMC 
and METH on basal and maximum respiration in undifferentiated cells correspond closely to those 
reported by us previously11. The enhanced sensitivity of undifferentiated cells limited us to performing 
subsequent experiments that investigated the involvement of Bcl-2, ROS and TNFα in cytotoxicity in 
undifferentiated cells in addition to the effect of DA-like phenotype in RA-TPA differentiated cells.
It has been previously shown that the overexpression of Bcl-2 protein reduces METH toxicity25 and 
that the BCL-2 family of genes may also play a role in regulating METH toxicity in vivo, in particular 
when very high drug doses are administered26,27. We showed that the protective effects of the overex-
pression of Bcl-2 found in this study extend to the treatment with high doses of cathinones in vitro as 
well. Conversely, we observed that the cathinones 4-MMC and MDMC, resulted in a spontaneous pro-
duction of ROS when in an aqueous solution, whereas this did not occur for the amphetamines METH 
and MDMA. It is therefore interesting that we observed that glutathione depletion with BSO had no 
effect on cathinone cytotoxicity as it did on cytotoxicity produced by METH and MDMA. This points 
towards an interesting difference in the interaction between amphetamines and cathinones on oxidative 
stress-related toxicity that warrants further investigation. The involvement of TNFα and p53 in amphet-
amine toxicity has previously been demonstrated both in vitro and in vivo28–32, and in the present study 
we demonstrated that these factors may also be involved in cathinone toxicity.
One limitation of this study is that the drug concentrations of up to 2 mM that were used to induce 
cytotoxicity and mitochondrial respiratory dysfunction, are much higher than those observed in human 
amphetamine users. However, this concentration is similar to concentrations used in previous studies 
Figure 9. Baseline oxygen consumption rate (OCR) and OCR following treatments with (A) 4-MMC 
or DMBA; (B) with MDMC or MDMBA or (C) with METH (all 2 mM), all followed by treatments with 
the complex V inhibitor oligomycin (Oli, final concentration 2 μM), the uncoupler carbonyl cyanide 
4-(trifluoromethoxy)phenylhydrazone (FCCP, final concentration 10 μM) and a combined treatment of 
the mitochondrial inhibitors rotenone and antimycin-A (Rot + Ama, final concentration 2 μM each). 
The assay was performed using the Seahorse Bioscience XFe96 analyzer in cells that had been permeabilized 
by recombinant perfringolysin O (2 nM) directly prior to the start of the assay. *p < 0.05; **p < 0.01; 
***p < 0.001 compared to control. N = 9–12 per group.
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on amphetamine toxicity33–36. A second limitation is that although SH-SY5Y cells are commonly used 
as in vitro models for studying DA-related neurological phenomena such as Parkinson’s disease and 
amphetamine neurotoxicity37, they are neuroblastoma cells. For these reasons, the results may not be 
directly translatable to humans but should be viewed mainly as a model for understanding mechanisms 
that may potentially play a role in the response of the human nervous system to amphetamines exposure.
Our results provide an important first insight into the mechanisms of cathinone cytotoxicity. These 
data emanate from in vitro experiments and they pave the way for further investigations into cathi-
none metabolism in vivo in addition to a broader evaluation of the specific contribution their metabolic 
breakdown products make to the total cytotoxicity. Therefore, future work is warranted that assesses the 
contribution of methylbenzamides and their potential interactions with cathinones in producing neuro-
toxicity under various circumstances in vivo.
Conclusion
Cathinones slowly but spontaneously degrade into their respective methylbenzamide breakdown products 
in aqueous solutions. The methylbenzamide products themselves possess toxic properties and contribute 
to the overall observed cathinone toxicity. When discriminating between the toxic effects of cathinones 
and their methylbenzamide breakdown products, the specific contribution of the cathinones per se may 
be quite limited. The breakdown of cathinones to methylbenzamides as well as the differential effects of 
cathinones and amphetamines on oxidative stress-related toxicity may contribute to an understanding 
of the toxicological differences between cathinones and amphetamines under various conditions in vivo, 
in addition to any discrepancies observed between in vivo and in vitro data.
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